Premium
Pulsed‐dye laser as an adjuvant treatment for papulopustular eruptions from epidermal growth factor receptor inhibitors, a randomized blinded split‐faced controlled trial
Author(s) -
Rerknimitr Pawinee,
Suphankong Yada,
Panchaprateep Ratchathorn,
Kerr Stephen J.,
Asawada Pravit
Publication year - 2019
Publication title -
lasers in surgery and medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.888
H-Index - 112
eISSN - 1096-9101
pISSN - 0196-8092
DOI - 10.1002/lsm.23080
Subject(s) - papulopustular , medicine , erythema , lesion , randomized controlled trial , surgery , dermatology , rosacea , acne
Objectives To investigate the efficacy of pulsed‐dye laser (PDL) as an adjunctive treatment for facial papulopustular eruptions from EGFR inhibitors (EGFRi). Methods Fourteen patients with facial acneiform eruptions were recruited. Half side of the face was randomized to receive PDL treatment while the other side served as a control. The treatments were delivered every 2 weeks for 4 sessions. The patients were seen at baseline, weeks 2, 4, 6, 8, and 10. Erythema index (EI) measured by colorimeter, the papulopustular lesion count and physician global assessment (PGA) were obtained. Patients were allowed to use their standard treatments for their eruptions. Results Both arms had a significant decrease in EI from baseline at each subsequent visit. In the laser treated side, the mean (95%CI) EI decreased from 23.5 (22.24–24.76) at baseline to 16.3 (15.01–17.59) at week 10, while those of the sham were 23.49 (22.23–24.75) to 20.51 (19.22–21.8), respectively. The mean change was significantly lower in the PDL arm from week 4 onwards. The lesion counts in both groups also decreased significantly, but the mean difference between the arms was not different. PGA scores followed the same pattern as EI. Conclusions Adjunctive treatment with PDL was a safe and effective treatment. Lasers Surg. Med. © 2019 Wiley Periodicals, Inc.